Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE

作者：Emma M. Kileel, Carlos Malvestutto, Markella V. Zanni, Emma Davies-Smith, Carl J Fichtenbaum, Jordan E. Lake, Janet Lo, Judith A. Aberg, Esteban Martinez, Kunjal Patel, Gerald S. Bloomfield, Sarah M Chu, Aya Awwad, Marissa R Diggs, Alex B Lu, Sara H Bares, Daniel Berrner, Marek Smieja, Nwora Lance Okeke, Princy Kumar, Esau João, Judith S Currier, Michael T. Lu, Matthew P Fox, Alana T. Brennan, Pamela S Douglas, Steven Grinspoon, Heather J Ribaudo · 发表于：The Lancet HIV · 年份：2026 · DOI：10.1016/s2352-3018(25)00354-6 · 被引用次数：2 · 研究领域：Diabetes Treatment and Management、Protein Kinase Regulation and GTPase Signaling、Phosphodiesterase function and regulation